Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 48.35 EUR 2.11%
Market Cap: 468m EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+75%
Revenue
Forecast
+14%
Operating Income
Forecast
+15%
Net Income
Forecast
+24%

Wall Street
Price Targets

PHN Price Targets Summary
Pharmanutra SpA

Wall Street analysts forecast PHN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHN is 84.66 EUR with a low forecast of 74.74 EUR and a high forecast of 92.4 EUR.

PHN Lowest Forecast
Wall Street Target
74.74 EUR
55% Upside
PHN Average Forecast
Wall Street Target
84.66 EUR
75% Upside
PHN Highest Forecast
Wall Street Target
92.4 EUR
91% Upside
Lowest
Price Target
74.74 EUR
55% Upside
Average
Price Target
84.66 EUR
75% Upside
Highest
Price Target
92.4 EUR
91% Upside
Pharmanutra SpA Competitors:
Price Targets
S
2145
Shanghai Chicmax Cosmetic Co Ltd
21% Upside
2931
Euglena Co Ltd
55% Upside
ITP
Interparfums SA
38% Upside
BEI
Beiersdorf AG
25% Upside
S
2145
Shanghai Chicmax Cosmetic Co Ltd
21% Upside
2931
Euglena Co Ltd
55% Upside
ITP
Interparfums SA
38% Upside
BEI
Beiersdorf AG
25% Upside
4452
Kao Corp
22% Upside
K
KAREX
Karex Bhd
41% Upside
BRBR
Bellring Brands Inc
17% Upside
4927
Pola Orbis Holdings Inc
4% Upside

Revenue
Forecast

Revenue Estimate
Pharmanutra SpA

For the last 7 years the compound annual growth rate for Pharmanutra SpA's revenue is 17%. The projected CAGR for the next 3 years is 14%.

17%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Pharmanutra SpA

For the last 7 years the compound annual growth rate for Pharmanutra SpA's operating income is 21%. The projected CAGR for the next 4 years is 13%.

21%
Past Growth
13%
Estimated Growth
Estimates Accuracy
6%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Pharmanutra SpA

For the last 7 years the compound annual growth rate for Pharmanutra SpA's net income is 19%. The projected CAGR for the next 4 years is 20%.

19%
Past Growth
20%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

See Also

Summary
PHN intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHN stock valuation using valuation multiples.
Wall Street Estimates
PHN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PHN's stock price target?
Price Target
84.66 EUR

According to Wall Street analysts, the average 1-year price target for PHN is 84.66 EUR with a low forecast of 74.74 EUR and a high forecast of 92.4 EUR.

What is Pharmanutra SpA's Revenue forecast?
Projected CAGR
14%

For the last 7 years the compound annual growth rate for Pharmanutra SpA's revenue is 17%. The projected CAGR for the next 3 years is 14%.

What is Pharmanutra SpA's Operating Income forecast?
Projected CAGR
13%

For the last 7 years the compound annual growth rate for Pharmanutra SpA's operating income is 21%. The projected CAGR for the next 4 years is 13%.

What is Pharmanutra SpA's Net Income forecast?
Projected CAGR
20%

For the last 7 years the compound annual growth rate for Pharmanutra SpA's net income is 19%. The projected CAGR for the next 4 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.